A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Infants

Completed · Phase 3

Conditions studied: HIV Infections, Pregnancy

In brief

The purpose of this study is to see if giving the anti-HIV drug nevirapine (NVP) to HIV-positive pregnant women and their infants can help reduce the chance that a mother will give HIV to her baby during delivery. NVP is a promising medication for blocking HIV transmission from HIV-positive mothers to their infants. NVP is inexpensive and is easily absorbed by the mother and transferred to the infant. It is thought that even a single dose to the mother and infant may provide enough protection to the baby during the time of exposure to HIV at birth.

Key facts

Study ID
NCT00001135
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
2009
Expected to finish
2001-05-01
Last updated by the study team
2021-11-01

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.